caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
It belongs to the sirtuin modulator class of molecules. | Cc1cc(OCC(O)CO)nc(NC(=O)N2CCC(C)(C)c3ccc(-c4cccc(C(F)(F)F)c4)nc32)n1 | [
"sirtuin modulator"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a syk inhibitor and a kinase inhibitor. | Fc1ccccc1-c1ccnn1-c1ccc(N2CCN(C3CC3)CC2)cc1 | [
"syk inhibitor",
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti inflammatory. | CC(C)(C)N1CCNC12CCNCC2 | [
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation that impacts tangier disease, aging, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, nut skin, burnt, and cocoa. The molecule is a flavoring agent, corn, sulfurous, and green. | C/C=C(/C=O)CCCC | [
"nutrient",
"nut skin",
"burnt",
"cocoa",
"corn",
"Flavoring agent",
"sulfurous",
"green"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a coagulation inhibitor, a factor xa inhibitor, and anti coagulant. | CCOC(=O)CCC(NC)C(C)=O | [
"anti coagulant",
"coagulation inhibitor",
"factor xa inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts non-alcoholic fatty liver disease and aging. | CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory and belongs to the anti neoplastic class of molecules. | CCC1(c2ccc(-c3cc(C(C)C)cc4c5c([nH]c34)C(CCO)OCC5)cc2F)C=CC=CC1 | [
"anti neoplastic",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, alzheimer's disease, non-alcoholic fatty liver disease, and diabetes mellitus type 2. | CCCCC/C=C\C/C=C\C/C=C\CC1OC1CCCC(=O)OC[C@H](COP(=O)(O)OCCN)O/C=C/CCCCCCCCCCCCCC | [
"Parkinson's disease",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCC(=O)OC(C)c1ccccc1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a p2y12 antagonist, a platelet aggregation inhibitor, and thrombosis treatment. | CCOC(=O)N1CCN(C(=O)C(CCC(=O)O)NC(=O)c2cc(NCC(=O)O)nc(-c3ccccc3)n2)CC1.Cl | [
"thrombosis treatment",
"p2y12 antagonist",
"platelet aggregation inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, aging, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a p2y12 antagonist and a platelet aggregation inhibitor, belonging to the thrombosis treatment class of molecules. | CCOC(=O)N1CCN(C(=O)C(CCC(=O)O)NC(=O)c2cc(NC(C)COC)nc(-c3ccccc3)n2)CC1 | [
"p2y12 antagonist",
"platelet aggregation inhibitor",
"thrombosis treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts tangier disease and aging. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Aging",
"Apoptosis",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the light-emitting class of molecules. | CS(=O)(=O)Oc1ccc(CCCCc2ccc3c(c2)CC3)cc1 | [
"light-emitting"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects cervical cancer by impacting breast cancer, ulcerative colitis, and atherosclerosis. | CCCCC/C=C\C=C/[C@@H](O)C/C=C\C/C=C/CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Breast cancer",
"Ulcerative colitis",
"Cervical cancer",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on improved luminous efficiency. | c1ccc(-c2nc(-c3ccc(-c4nc(-c5cccc(-c6cccc(-c7cc(-c8ccc9c(c8)C8(c%10ccccc%10-c%10ccccc%108)c8ccccc8-9)nc(-c8cccc9c8-c8ccccc8C9(c8ccccc8)c8ccccc8)n7)c6)c5)nc(-c5ccc6ccc7cccnc7c6n5)n4)cc3)nc3ccccc23)cc1 | [
"improved luminous efficiency"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts atherosclerosis, cardiovascular disease, and pancreatitis. The molecule is a nutrient and a fat storage, impacting both metabolic syndrome and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Atherosclerosis",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"Thyroxine treatment",
"nutrient",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti allergic member of the anti allergic agent class. | CCCCCCCCCCOc1c(OC(C)=O)c2c(OC(C)=O)cccc2oc1=O | [
"anti allergic",
"anti allergic agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti malarial class of molecules. | Cc1ccc(C#N)cc1-n1c(=N)n(C)c2cnc3ccc(-c4cccc(CN(C)C)c4)cc3c21 | [
"anti malarial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. | CCCCCC/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cdk inhibitor. | C=CC(=O)Nc1ccc(C(=O)N2CCC(Nc3ncc(C4CC4)cn3)C2)cc1 | [
"cdk inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a vap1 inhibitor. | Cc1ccc(N2CCC(OC3CN(c4cccc(COC(=O)N=C(N)N)c4F)C3)CC2)cn1 | [
"vap1 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a membrane stabilizer, impacting both tangier disease and barth syndrome. The molecule is a energy source, surfactant, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a nutritional supplem... | CCC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Membrane stabilizer",
"Energy source",
"surfactant",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Aging",
"Nutritional supplement",
"Energy storage",
"Apoptosis",... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts aging and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a respirastimulant and a secretomotor, as well as anti insomniac and anti tachycardic. The molecule is a personal care products and platelet aggregation factor inhibitor, belonging to the anti lipolytic class of molecules, and is anti arrhythmic. The molecule is a immunotoxin and anti diuretic, belongin... | Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | [
"anti insomniac",
"respirastimulant",
"anti tachycardic",
"secretomotor",
"anti arrhythmic",
"Personal care products",
"anti lipolytic",
"platelet aggregation factor inhibitor",
"Immunotoxin",
"anti arrhythmia drug",
"anti diuretic",
"anxiolytic",
"Pharmaceutical",
"human metabolite",
"h... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts atherosclerosis, ulcerative colitis, cervical cancer, and breast cancer. | CCCCCCCC/C=C/C/C=C/C=C/C(O)CCCC(=O)O[C@H](CO/C=C/CCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"nutrient",
"Atherosclerosis",
"Ulcerative colitis",
"Cervical cancer",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti viral. | COC(=O)CCCCCCCCOC1OC(C)C(O)C(OC(C)=O)C1OC1OC(COC(C)=O)C(OCc2ccccc2)C(OCc2ccccc2)C1OCc1ccccc1 | [
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, fat storage, inflammatory that impacts metabolic syndrome, cancer, and atherosclerosis. The molecule is a nutrient and thyroxine treatment, and it impacts pancreatitis. The molecule is a membrane stabilizer and a energy storage, impacting both obesity and cardiovascular disease. | CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCC(C)C | [
"Metabolic syndrome",
"Cancer",
"Atherosclerosis",
"Energy source",
"Fat storage",
"inflammatory",
"Thyroxine treatment",
"nutrient",
"Pancreatitis",
"Obesity",
"Cardiovascular disease",
"Membrane stabilizer",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a hiv treatment and a hiv integrase inhibitor. | COc1nc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C)cn2C(CO)C(C)C | [
"hiv treatment",
"hiv integrase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and aging. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the metabolic syndrome treatment class and affects obesity treatment. | CCCCn1nc2c(c1NC(=O)CS(C)(=O)=O)C(=O)NC1(CCc3cc(OCCCC(F)(F)F)ccc31)C2 | [
"obesity treatment",
"metabolic syndrome treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts atherosclerosis and ulcerative colitis. | CCCCCc1oc(CCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC[C@@H](O)CC)COP(=O)([O-])OCC[N+](C)(C)C)c(C)c1C | [
"nutrient",
"Breast cancer",
"Atherosclerosis",
"Cervical cancer",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy storage, fat storage that impacts cardiovascular disease, atherosclerosis, and metabolic syndrome. The molecule affects cancer, has an impact on pancreatitis, and is characterized as thyroxine treatment. The molecule is a energy source, a membrane stabilizer, and a nutrient, and i... | CCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Energy storage",
"Cardiovascular disease",
"Atherosclerosis",
"Fat storage",
"Metabolic syndrome",
"Pancreatitis",
"Cancer",
"Thyroxine treatment",
"Energy source",
"Membrane stabilizer",
"nutrient",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and barth syndrome. The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and metabolic syndrome. The molecule is a nutrient and thyroxine treatment, impacting both atherosclerosis and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC | [
"Fat storage",
"Cardiovascular disease",
"Metabolic syndrome",
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts parkinson's disease, alzheimer's disease, and diabetes mellitus. It impacts seizure, colorectal cancer, stomach cancer, and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@@H]1COP(=O)(O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CCCCCCC(=O)O1)C(=O)C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@H](O)[C@H]2O | [
"Parkinson's disease",
"Alzheimer's Disease",
"Diabetes mellitus",
"Breast cancer",
"Seizure",
"Colorectal cancer",
"Stomach cancer",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy storage, nutrient that impacts cardiovascular disease, cancer, and pancreatitis. The molecule is a inflammatory that impacts both metabolic syndrome and obesity. The molecule is a fat storage and a energy source, it impacts atherosclerosis, and is thyroxine treatment. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCC | [
"Cardiovascular disease",
"Membrane stabilizer",
"Cancer",
"Pancreatitis",
"Energy storage",
"nutrient",
"Metabolic syndrome",
"Obesity",
"inflammatory",
"Atherosclerosis",
"Fat storage",
"Thyroxine treatment",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both metabolic syndrome and cardiovascular disease. The molecule is a nutrient and a thyroxine treatment, impacting both atherosclerosis and pancreatitis. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCC | [
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"nutrient",
"Atherosclerosis",
"Thyroxine treatment",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease and barth syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts alzheimer's treatment. | COc1cc(Br)cc2c1OC(C(C)C)C(=O)N(C1CCN(Cc3ccccc3)CC1)C2C(=O)NC(C)(C)C | [
"alzheimer's treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, a energy storage, and a inflammatory that impacts both pancreatitis and atherosclerosis, and is thyroxine treatment. The molecule is a nutrient that impacts both cancer and metabolic syndrome. The molecule is a fat storage and a membrane stabilizer, impacting both cardiovascular disease... | CCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis",
"Energy source",
"Energy storage",
"inflammatory",
"Cancer",
"Metabolic syndrome",
"nutrient",
"Fat storage",
"Membrane stabilizer",
"Cardiovascular disease",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a wnt pathway inhibitor. | CN(C)CCOc1cc(F)cc(-c2ccnc3nc(-c4n[nH]c5ccc(-c6cncc(NC(=O)C7CC7)c6)nc45)[nH]c23)c1 | [
"wnt pathway inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a surfactant, and a energy source. The molecule is a nutrient, signalling molecule, membrane stabilizer, energy storage. | Cc1cc(=O)c2c(CC(=O)O)cc(O)cc2o1 | [
"Emulsifier",
"surfactant",
"Energy source",
"nutrient",
"signalling molecule",
"Membrane stabilizer",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a flavoring agent, fennel, green with a Resembles that of vanillin but approximately 3 times as strong.. When heated to decomposition it emits acrid smoke and irritating fumes. The molecule is sweet. The molecule is a bitter, is new mown hay, and has a Finer and more intense taste than vanillin. | CCOc1cc(C=O)ccc1O | [
"Flavoring agent",
"fennel",
"green",
"Odor_evaluation",
"Decomposition_evaluation",
"sweet",
"new mown hay",
"bitter",
"taste_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, alzheimer's disease, and parkinson's disease. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)C/C=C\C[C@H]1[C@@H](/C=C/[C@H](O)CCCCC)[C@H](O)C[C@@H]1O | [
"Diabetes mellitus type 2",
"nutrient",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hcv inhibitor and belongs to the anti viral class of molecules. | COC(=O)NC(C(=O)N1CCCC1C(=O)NC1CCc2cc(-c3ccc(-c4cnc(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)[nH]4)cc3)ccc2C1)C(C)C | [
"hcv inhibitor",
"anti viral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, alzheimer's disease, and diabetes mellitus type 2. | CC/C=C/CC(O)/C=C/C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"nutrient",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)C | [
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure that impacts diabetic heart disease and barth syndrome. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is light-emitting. | c1ccc(-c2cc(-c3ccccc3)nc(-c3cc(-c4ccc(-c5ccccn5)cc4)cc(-c4cccc(-c5ccccn5)c4)c3)n2)cc1 | [
"light-emitting"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts seizure, diabetes mellitus, parkinson's disease, and cardiovascular disease. It has an effect on stomach cancer, and impacts breast cancer, alzheimer's disease, and colorectal cancer. | CCCCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC[C@H](O)CC | [
"Seizure",
"Diabetes mellitus",
"Parkinson's disease",
"Cardiovascular disease",
"Breast cancer",
"Alzheimer's Disease",
"Colorectal cancer",
"Stomach cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Slight odor. | CN(C)C(CSC(N)=O)CSC(N)=O.Cl | [
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that affects breast cancer by impacting both cardiovascular disease and diabetes mellitus type 2. It impacts inflammatory bowel disease, heart failure, celiac disease, and renal cell carcinoma. | CC(C)C=CCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Cardiovascular disease",
"Breast cancer",
"Diabetes mellitus type 2",
"Energy source",
"Inflammatory bowel disease",
"Heart failure",
"Celiac disease",
"Renal cell carcinoma"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, membrane stabilizer, inflammatory that belongs to the thyroxine treatment class of molecules and impacts both metabolic syndrome and obesity. The molecule is a energy source that impacts both atherosclerosis and cancer. The molecule is a nutrient and a energy storage, impacting both cardi... | CCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Fat storage",
"Membrane stabilizer",
"Metabolic syndrome",
"inflammatory",
"Obesity",
"Energy source",
"Atherosclerosis",
"Cancer",
"Cardiovascular disease",
"nutrient",
"Energy storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, surfactant, emulsifier, energy storage, nutrient. | COc1cc(C(=O)OCC2(O)COC(OC3C(Oc4ccc(C(C)=O)cc4)OC(CO)C(O)C3O)C2O)cc(OC)c1O | [
"Membrane stabilizer",
"Energy source",
"surfactant",
"Emulsifier",
"Energy storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits acrid smoke and irritating fumes. The molecule has Slight hay-like odor. | O=c1ccc2ccc3occc3c2o1 | [
"Decomposition_evaluation",
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti infective that is anti inflammatory and anti allergic. | CC(=O)c1ccnc(C(C)=O)c1 | [
"anti inflammatory",
"anti infective",
"anti allergic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, a emulsifier, and a energy storage that impacts both alzheimer's disease and diabetes mellitus type 2, and is smooth. The molecule is a membrane stabilizer and surfactant, and it impacts non-alcoholic fatty liver disease. The molecule is a energy source, a food additive, and a nutritional su... | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OCCN | [
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Smooth",
"nutrient",
"Emulsifier",
"Energy storage",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"surfactant",
"Energy source",
"Parkinson's disease",
"food additive",
"Nutritional supplement"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and tangier disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts non-alcoholic fatty liver disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure that impacts aging and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C=C/C(O)C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and aging. | CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is pain treatment. | CC(C)(CN1C(=O)c2ccccc2C1C(=O)NCc1ccc(OC(F)(F)F)cc1)c1ccccn1 | [
"pain treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that impacts breast cancer, cardiovascular disease, and diabetes mellitus type 2. It impacts heart failure, celiac disease, renal cell carcinoma, and inflammatory bowel disease. | CCCCCCCCCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Breast cancer",
"Cardiovascular disease",
"Diabetes mellitus type 2",
"Energy source",
"Heart failure",
"Celiac disease",
"Renal cell carcinoma",
"Inflammatory bowel disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts tangier disease, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts diabetic heart disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and tangier disease. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and nutrient, and it impacts metabolic syndrome. The molecule is a member of the thyroxine treatment class and affects pancreatitis, atherosclerosis, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Metabolic syndrome",
"Fat storage",
"nutrient",
"Pancreatitis",
"Atherosclerosis",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C/C(=O)/C=C\c1ccc(O)c(OC)c1 | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pi3k inhibitor. | COc1cc(OC)cc(C2(CO)C(C)(O)CCC3C(C)(C)CCCC32C)c1 | [
"pi3k inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a gcn2 inhibitor and is treatment of disorder. | CN1CCN(c2cc(-c3cnc(C=CC(=N)C(F)F)[nH]3)ccn2)CC1CO | [
"treatment of disorder",
"gcn2 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, surfactant, energy storage, nutritional supplement. It impacts non-alcoholic fatty liver disease, diabetic heart disease, tangier disease, aging, and barth syndrome. The molecule is a cholesterol translocation, a proton trap for oxidative phosphorylation, a energy sourc... | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"surfactant",
"Energy storage",
"Nutritional supplement",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Barth syndrome",
"Smooth",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Energy... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and aging. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, barth syndrome, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and pancreatitis. The molecule is a nutrient that impacts cardiovascular disease, metabolic syndrome, and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Fat storage",
"Atherosclerosis",
"Pancreatitis",
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, tangier disease, and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both pancreatitis and atherosclerosis. The molecule is a thyroxine treatment and a fat storage, impacting both metabolic syndrome and cardiovascular disease. | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Pancreatitis",
"Atherosclerosis",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy source, nutrient that impacts metabolic syndrome, thyroxine treatment, and atherosclerosis. The molecule is a fat storage that impacts both pancreatitis and obesity. The molecule is a energy storage and a membrane stabilizer, with effects on cancer and impacts on cardiovascular di... | CCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Metabolic syndrome",
"Thyroxine treatment",
"Energy source",
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Obesity",
"Fat storage",
"Cancer",
"Cardiovascular disease",
"Energy storage",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutritional supplement, a signalling molecule, and a food additive. The molecule is a membrane stabilizer, energy source, emulsifier, surfactant. The molecule is a energy storage, a nutrient, and smooth. The molecule is a insulin signaling antagonist and a inflammatory, with effects on lipotoxicity an... | COc1cc(OC)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)C1CCCC(C)(O3)O1 | [
"Nutritional supplement",
"signalling molecule",
"food additive",
"Membrane stabilizer",
"Energy source",
"Emulsifier",
"surfactant",
"Energy storage",
"nutrient",
"Smooth",
"Metabolic syndrome",
"Lipotoxicity",
"insulin signaling antagonist",
"inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts barth syndrome, non-alcoholic fatty liver disease, tangier disease, and aging. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts tangier disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging, barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on stomach cancer, and impacts cardiovascular disease, seizure, and alzheimer's disease. It has an effect on colorectal cancer, and impacts parkinson's disease, breast cancer, and diabetes mellitus. | CC/C=C\C[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)/C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCCCCCCCCCC | [
"Stomach cancer",
"Cardiovascular disease",
"Seizure",
"Alzheimer's Disease",
"Parkinson's disease",
"Colorectal cancer",
"Breast cancer",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts aging, barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure. It impacts non-alcoholic fatty liver disease, diabetic heart disease, tangier disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a chemokine receptor modulator and belongs to the inflammation treatment class of molecules. | CCCCCN(Cc1nccc2c3ccccc3n(CC(=O)N3CCC(F)(F)CC3)c12)C1CCCc2cccnc21 | [
"chemokine receptor modulator",
"inflammation treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer and a energy source, impacting both non-alcoholic fatty liver disease and aging. The molecule is a nutritional supplement, cholesterol translocation, proton trap for oxidative phosphorylation that impacts diabetic heart disease and tangier disease. The molecule is a energy storage,... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Aging",
"Energy source",
"Diabetic heart disease",
"Nutritional supplement",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Energy storage",
"Barth syndrome",
"Stabilizing mitochondrial ... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts barth syndrome, tangier disease, and aging. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. | CCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting atherosclerosis. The molecule is a fat storage that impacts pancreatitis, cardiovascular disease, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Thyroxine treatment",
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Fat storage",
"Cardiovascular disease",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, a proton trap for oxidative phosphorylation, and a surfactant, and it impacts non-alcoholic fatty liver disease. The molecule is a energy storage, emulsifier, energy source, food additive that impacts tangier disease. The molecule is a cholesterol translocation and a membrane stabilizer, it... | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"surfactant",
"Non-alcoholic fatty liver disease",
"Energy storage",
"Emulsifier",
"Energy source",
"Tangier disease",
"food additive",
"Cholesterol translocation",
"Membrane stabilizer",
"Smooth",
"Aging",
"Stabilizing mitochondria... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is leaf, nut, herbal, as well as fresh and cucumber, and has a Ethereal. The molecule is waxy. When heated to decomposition it emits acrid smoke and irritating fumes. The molecule is banana. The molecule is fatty, green, and fat. | c1ccoc1 | [
"leaf",
"nut",
"herbal",
"fresh",
"Odor_evaluation",
"cucumber",
"waxy",
"Decomposition_evaluation",
"banana",
"fatty",
"green",
"fat"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a histone deacetylase inhibitor. | CC(C)(C)OC(=O)Nc1cc(-c2ccc(CO)s2)ccc1[N+](=O)[O-] | [
"histone deacetylase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts tangier disease and barth syndrome. The molecule is a cholesterol translocation and a apoptosis that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.